On June 27, Incyte rose 5.84% in regular trading, trading at $113.78/share, with turnover of $140 million. The rally was driven by the company's announcement that its Opzelura cream received a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP), recommending approval for adults with moderate atopic dermatitis who have not responded adequately to standard topical therapies.

The CHMP recommendation is based on Phase 3 TRuE-AD4 data showing significant improvements in disease severity and symptoms, with the treatment generally well tolerated. If approved by the European Commission, Opzelura would become the first steroid-free topical JAK inhibitor in the EU for this patient population. This regulatory milestone represents a key step toward expanding the drug's commercial footprint in Europe, adding to Incyte's growing portfolio across hematology, oncology, and inflammation therapeutics.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)